Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for NVAX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 34.90M
March 31, 2026 -28.36M
December 31, 2025 20.48M
September 30, 2025 -136.53M
June 30, 2025 111.10M
March 31, 2025 -73.32M
December 31, 2024 144.01M
September 30, 2024 31.91M
June 30, 2024 -372.71M
March 31, 2024 -7.25M
December 31, 2023 -9.078M
September 30, 2023 -18.39M
June 30, 2023 -7.779M
March 31, 2023 -23.56M
December 31, 2022 -22.06M
September 30, 2022 -29.52M
June 30, 2022 -24.58M
March 31, 2022 -16.83M
December 31, 2021 -16.36M
September 30, 2021 -12.19M
June 30, 2021 -12.90M
March 31, 2021 141.61M
December 31, 2020 -31.12M
September 30, 2020 -100.71M
June 30, 2020 -188.22M
Date Value
March 31, 2020 -57.73M
December 31, 2019 -0.216M
September 30, 2019 17.97M
June 30, 2019 2.024M
March 31, 2019 18.71M
December 31, 2018 48.32M
September 30, 2018 7.996M
June 30, 2018 -48.30M
March 31, 2018 20.59M
December 31, 2017 16.76M
September 30, 2017 41.96M
June 30, 2017 2.531M
March 31, 2017 -25.28M
December 31, 2016 85.90M
September 30, 2016 92.57M
June 30, 2016 18.98M
March 31, 2016 -169.44M
December 31, 2015 9.559M
September 30, 2015 -9.21M
June 30, 2015 -39.41M
March 31, 2015 17.79M
December 31, 2014 17.35M
September 30, 2014 -54.10M
June 30, 2014 -102.78M
March 31, 2014 9.701M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Moderna, Inc. 329.00M
Merck & Co., Inc. -5.602B
Pfizer Inc. 2.106B
Recursion Pharmaceuticals, Inc. -1.959M
Agenus, Inc. 0.267M